

NEUROLOGIX INC/DE  
Form 10-Q  
August 12, 2009

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-Q**

**(Mark One)**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarter ended June 30, 2009**

**or**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 000-13347**

**NEUROLOGIX, INC.**

(Exact name of Registrant as specified in its charter)

**Delaware**

**06-1582875**

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

**One Bridge Plaza, Fort Lee, NJ 07024**

(Address of principal executive offices)

**(201) 592-6451**

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
Yes  No

As of August 10, 2009, 27,865,010 shares of common stock were outstanding.



**TABLE OF CONTENTS**

	<b>Page</b>
<b>PART I. FINANCIAL INFORMATION</b>	
Item 1. Financial Statements	
<u>Condensed Balance Sheets (Unaudited)</u>	3
<u>Condensed Statements of Operations (Unaudited)</u>	4
<u>Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited)</u>	5 8
<u>Condensed Statements of Cash Flows (Unaudited)</u>	9 10
<u>Notes to Condensed Financial Statements (Unaudited)</u>	11 18
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3. Quantitative and Qualitative Disclosures About Market Risk	24
Item 4. Controls and Procedures	24
<b><u>PART II. OTHER INFORMATION</u></b>	
Item 4. Submission of Matters to a Vote of Security Holders	25
Item 6. Exhibits	25
<u>Exhibit 31.1</u>	
<u>Exhibit 31.2</u>	
<u>Exhibit 32.1</u>	

---

**Table of Contents**

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**CONDENSED BALANCE SHEETS**  
(Amounts in thousands, except share and per share amounts)

	<b>June 30, 2009</b>	<b>December 31, 2008</b>
	(Unaudited)	
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 14,736	\$ 18,906
Prepaid expenses and other current assets	315	323
Total current assets	15,051	19,229
Equipment, less accumulated depreciation of \$584 and \$542 at June 30, 2009 and December 31, 2008, respectively	128	141
Intangible assets, less accumulated amortization of \$222 and \$182 at June 30, 2009 and December 31, 2008, respectively	836	748
Other assets	5	5
Total Assets	\$ 16,020	\$ 20,123
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
Current liabilities:		
Accounts payable and accrued expenses	\$ 1,489	\$ 850
Total current liabilities	1,489	850
Derivative financial instruments, at estimated fair value Warrants	3,050	
Total liabilities	4,539	850
Commitments and contingencies		
Stockholders' equity:		
Preferred stock; 5,000,000 shares authorized		
Series A Convertible, \$0.10 par value; 650 shares designated, 645 shares issued and outstanding at June 30, 2009 and December 31, 2008, with an aggregate liquidation preference of \$1		
Series C Convertible, \$0.10 par value; 700,000 shares designated, 281,263 and 285,878 shares issued and outstanding at June 30, 2009 and December 31, 2008, respectively, with an aggregate liquidation preference of \$6,558 and \$5,863 at June 30, 2009 and December 31, 2008, respectively	28	29
Series D Convertible, \$0.10 par value; 792,100 shares designated, 734,898 shares issued and outstanding at June 30, 2009 and December 31, 2008, with an aggregate liquidation preference of \$28,392 and \$27,031 at June 30, 2009 and December 31, 2008, respectively	73	73
Common Stock:		

Edgar Filing: NEUROLOGIX INC/DE - Form 10-Q

\$0.001 par value; 100,000,000 shares authorized, 27,865,010 and 27,764,058 issued and outstanding at June 30, 2009 and December 31, 2008, respectively	28	28
Additional paid-in capital	56,557	62,393
Deficit accumulated during the development stage	(45,205)	(43,250)
Total stockholders' equity	11,481	19,273
Total Liabilities and Stockholders' Equity	\$ 16,020	\$ 20,123

See accompanying notes to condensed financial statements.

**Table of Contents**

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**CONDENSED STATEMENTS OF OPERATIONS**  
**(UNAUDITED)**

(Amounts in thousands, except share and per share amounts)

	Six Months Ended June 30,		Three Months Ended June 30,		For the period February 12, 1999 (inception) through June 30, 2009
	2009	2008	2009	2008	
Revenues	\$	\$	\$	\$	\$
Operating expenses:					
Research and development	3,658	1,829	2,249	747	23,275
General and administrative expenses	1,548	1,761	799	839	17,648
Loss from operations	(5,206)	(3,590)	(3,048)	(1,586)	(40,923)
Other income (expense):					
Dividend, interest and other income	49	311	16	155	1,875
Interest expense-related parties					(411)
Change in estimated fair value of derivative financial instruments					
Warrants	(1,980)		809		(1,980)
Other income (expense), net	(1,931)	311	825	155	(516)
Net loss	(7,137)	(3,279)	(2,223)	(1,431)	\$ (41,439)
Preferred stock dividends	(1,451)	(1,230)	(734)	(641)	
Charge for accretion of beneficial conversion feature		(562)		(562)	
Charge for contingent beneficial conversion feature		(212)		(212)	

Edgar Filing: NEUROLOGIX INC/DE - Form 10-Q

Net loss applicable to common stock	\$	(8,588)	\$	(5,283)	\$	(2,957)	\$	(2,846)
-------------------------------------	----	---------	----	---------	----	---------	----	---------

Net loss applicable to common stock per share, basic and diluted	\$	(0.31)	\$	(0.19)	\$	(0.11)	\$	(0.10)
---------------------------------------------------------------------	----	--------	----	--------	----	--------	----	--------

Weighted average common shares outstanding, basic and diluted	27,795,850	27,632,808	27,827,292	27,632,808
------------------------------------------------------------------	------------	------------	------------	------------

See accompanying notes to condensed financial statements.



Table of Contents

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)**  
**FOR THE PERIOD FROM FEBRUARY 12, 1999 (INCEPTION) THROUGH JUNE 30, 2009**  
**(UNAUDITED)**

(Amounts in thousands, except for share and per share amounts)

	Series D Preferred Stock		Series C Preferred Stock		Common Stock		Additional Paid-in Capital		Unearned Development	Deficit Accumulated During the	Total
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Compensation	Stage		
Sale of common stock to founders		\$ 0		\$ 0	6,004,146	\$ 0	\$ 4	\$ 0	\$ 0	\$ 0	\$ 4
Net loss										(328)	(328)
<b>Balance, December 31, 1999</b>		\$ 0		\$ 0	6,004,146	\$ 0	\$ 4	\$ 0	\$ 0	(328)	\$ (324)
Net loss										(1,055)	(1,055)
<b>Balance, December 31, 2000</b>		\$ 0		\$ 0	6,004,146	\$ 0	\$ 4	\$ 0	\$ 0	(1,383)	\$ (1,379)
Stock options granted for services								9			9
Common stock issued for intangible assets at \$0.09 per share					259,491		24				24
Net loss										(870)	(870)
<b>Balance, December 31, 2001</b>		\$ 0		\$ 0	6,263,637	\$ 0	\$ 37	\$ 0	\$ 0	(2,253)	\$ (2,216)
Retirement of founder shares					(33,126)						
Common Stock issued pursuant to license agreement at \$1.56 per share					368,761		577	(577)			
Private placement of Series B convertible preferred stock							2,613				2,613
Amortization of unearned								24			24

compensation									
Net loss							(1,310)		(1,310)
<b>Balance,</b>									
<b>December 31,</b>									
<b>2002</b>	\$ 0	\$ 0	6,599,272	\$ 0	\$ 3,227	\$ (553)	\$ (3,563)	\$ (889)	
Sale of Common Stock			276,054		90	(89)			1
Amortization of unearned compensation						164			164
Net loss							(2,274)		(2,274)
<b>Balance,</b>									
<b>December 31,</b>									
<b>2003</b>	\$ 0	\$ 0	6,875,326	\$ 0	\$ 3,317	\$ (478)	\$ (5,837)	\$ (2,998)	
Conversion of note payable to Common Stock at \$2.17 per share			1,091,321	1	2,371				2,372
Conversion of mandatory redeemable preferred stock to Common Stock			6,086,991	6	494				500
Conversion of Series B convertible preferred stock to Common Stock			1,354,746	1	(1)				
Effects of reverse acquisition			7,103,020	14	5,886				5,900
Amortization of unearned compensation						202			202

Table of Contents

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)**  
**FOR THE PERIOD FROM FEBRUARY 12, 1999 (INCEPTION) THROUGH JUNE 30, 2009**  
**(UNAUDITED)**

(Amounts in thousands, except for share and per share amounts)

	Series D	Series C	Common Stock	Additional	Unearned	Development	Deficit	
	Preferred Stock	Preferred Stock	Common Stock	Paid-in	Compensation	Stage	Accumulated	Total
	Shares	Shares	Shares	Capital			During	
	Amount	Amount	Amount				the	
Stock options granted for services				42		(42)		
Exercise of stock options			10,000	15				15
Net loss							(2,937)	(2,937)
<b>Balance, December 31, 2004</b>	\$ 0	\$ 0	22,521,404	\$ 22	\$ 12,124	\$ (318)	\$ (8,774)	\$ 3,054
Sale of Common Stock through private placement at an average price of \$1.30 per share			2,473,914	4	3,062			3,066
Sale of Common Stock at an average price of \$1.752 per share and warrants to Medtronic			1,141,552	1	2,794			2,795
Amortization of unearned compensation						825		825
Stock options granted for services				1,305		(1,305)		
Exercise of stock options			406,054	127				127
Net loss							(5,345)	(5,345)
<b>Balance, December 31, 2005</b>	\$ 0	\$ 0	26,542,924	\$ 27	\$ 19,412	\$ (798)	\$ (14,119)	\$ 4,522
		342,857	34		11,578			11,612

Sale of Preferred Stock through private placement at an average price of \$35.00 per share										
Fair value of beneficial conversion rights issued in connection with issuance of Series C Preferred Stock						2,621			2,621	
Dividend and accretion of fair value of beneficial conversion charge	25,298	3				(3)		(2,621)	(2,621)	
Employee share-based compensation expense						1,193			1,193	
Non-employee share-based compensation						83			83	
Reclassification of prior year non-employee compensation to prepaid expenses							487		487	
Effects of adoption of SFAS 123R						(311)	311			
Net loss								(7,046)	(7,046)	
<b>Balance, December 31, 2006</b>	\$ 0	368,155	\$ 37	26,542,924	\$ 27	\$ 34,573	\$	0	\$ (23,786)	\$ 10,851
Sale of Series D Preferred Stock through private placement at an average price of \$35.00 per share	428,571	43				14,727			14,770	

Table of Contents

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)**  
**FOR THE PERIOD FROM FEBRUARY 12, 1999 (INCEPTION) THROUGH JUNE 30, 2009**  
**(UNAUDITED)**

(Amounts in thousands, except for share and per share amounts)

	Series D Preferred Stock		Series C Preferred Stock		Common Stock		Additional Paid-in Unearned Capital	Development Stage	Deficit Accumulated During the	Total
	Shares	Amount	Shares	Amount	Shares	Amount	Compensation			
Fair value of beneficial conversion rights issued in connection with the issuance of Series D Preferred Stock							2,130			2,130
Preferred Dividend and accretion of fair value of beneficial conversion charge	5,108	1	68,801	7			(8)	(2,130)		(2,130)
Contingent beneficial conversion feature related to Series C Preferred Stock							627	(627)		
Induced conversion of preferred stock in connection with the issuance of Series D Preferred Stock	163,470	16	(230,184)	(23)			(347)	354		
Issuance of Series C Preferred Stock in connection with induced conversion of preferred stock			93,940	9			2,949	(2,958)		
					192,017		192	(192)		





Table of Contents

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)**  
**FOR THE PERIOD FROM FEBRUARY 12, 1999 (INCEPTION) THROUGH JUNE 30, 2009**  
**(UNAUDITED)**

(Amounts in thousands, except for share and per share amounts)

	Series D		Series C		Common Stock		Additional	Unearned	Development	Deficit	
	Preferred	Preferred	Preferred	Preferred	Common	Common	Paid-in	Compensation	Stage	Accumulated	Total
	Shares	Amount	Shares	Amount	Shares	Amount	Capital			During	
										the	
Employee share-based compensation expense							489				489
Non-employee share-based compensation							3				3
Conversion of Series C Preferred Stock to Common Stock			(6,000)		131,250						
Net Loss										(6,320)	(6,320)
<b>Balance December 31, 2008</b>	734,898	\$ 73	285,878	\$ 29	27,764,058	\$ 28	\$ 62,393	\$ 0	\$ (43,250)		\$ 19,273
Employee share-based compensation expense							305				305
Non-employee share-based compensation							110				110
Cumulative effect of adoption of EITF No. 07-05							(6,252)		5,182		(1,070)
Conversion of Series C Preferred Stock to Common Stock			(4,615)	(1)	100,952		1				
Net Loss										(7,137)	(7,137)
<b>Balance June 30, 2009</b>	734,898	\$ 73	281,263	\$ 28	27,865,010	\$ 28	\$ 56,557	\$ 0	\$ (45,205)		\$ 11,481



Edgar Filing: NEUROLOGIX INC/DE - Form 10-Q  
See accompanying notes to condensed financial statements.

**Table of Contents**

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**CONDENSED STATEMENTS OF CASH FLOWS**  
**(UNAUDITED)**  
**(Amounts in thousands)**

	Six Months Ended June 30,		For the period February 12, 1999 (inception)
	2009	2008	through June 30, 2009
Operating activities:			
Net loss	\$ (7,137)	\$ (3,279)	\$ (41,439)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation	42	58	590
Amortization	40	27	362
Gain on redemption of investment			(62)
Stock options granted for services			9
Impairment of intangible assets		29	194
Amortization of non-employee share-based compensation	132	18	1,611
Share-based employee compensation expense	305	325	2,689
Non-cash interest expense			378
Change in estimated fair value of derivative financial instruments	1,980		1,980
Changes in operating assets and liabilities			
(Increase) decrease in prepaid expenses and other current assets	(13)	84	640
Increase (decrease) in accounts payable and accrued expenses	638	(662)	1,427
Net cash used in operating activities	(4,013)	(3,400)	(31,621)
Investing activities:			
Security deposits paid			(7)
Purchases of equipment	(29)	(5)	(604)
Additions to intangible assets	(128)	(140)	(1,362)
Proceeds from redemption of investment			65
Purchases of marketable securities			(12,673)
Proceeds from maturities of marketable securities			12,673
Net cash used in investing activities	(157)	(145)	(1,908)
Financing activities:			
Proceeds from note payable			1,100
Borrowings from related party			2,000
Cash acquired in Merger			5,413
Merger-related costs			(375)

Edgar Filing: NEUROLOGIX INC/DE - Form 10-Q

Payments of capital lease obligations			(99)
Proceeds from exercise of stock options			733
Proceeds from issuance of common stock and warrants			5,066
Proceeds from issuance of preferred stock	4,957		34,427
Net cash provided by financing activities	4,957		48,265
Net (decrease) increase in cash and cash equivalents	(4,170)	1,412	14,736
Cash and cash equivalents, beginning of period	18,906	20,157	

**Table of Contents**

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**CONDENSED STATEMENTS OF CASH FLOWS**  
**(UNAUDITED)**  
**(Amounts in thousands)**

	Six Months Ended June 30,		For the period February 12, 1999 (inception)
	2009	2008	through June 30, 2009
Cash and cash equivalents, end of period	\$ 14,736	\$ 21,569	\$ 14,736
Supplemental disclosure of non-cash investing and financing activities:			
Dividends on Series C Preferred Stock paid in preferred shares	\$	\$	\$ 1,811
Accrued dividends on Preferred Stock	\$ 1,451	\$ 1,230	\$ 4,395
Accretion of fair value of beneficial conversion on preferred stock	\$	\$ 562	\$ 5,313
Accretion of contingent beneficial conversion related on Series C Preferred Stock	\$	\$ 212	\$ 839
Induced conversion of preferred stock in connection with issuance of Series D Preferred Stock	\$	\$	\$ 2,796
Issuance of Common Stock to pay debt	\$	\$	\$ 2,372
Reverse acquisition net liabilities assumed, excluding cash	\$	\$	\$ (214)
Mandatory redeemable convertible preferred stock converted to Common Stock	\$	\$	\$ 500
Common Stock issued to acquire intangible assets	\$	\$	\$ 24
Stock options granted for services	\$	\$	\$ 1,424
Deferred research and development cost resulting from Medtronic Stock Purchase	\$	\$	\$ 795
Acquisition of equipment through capital leases	\$	\$	\$ 106

See accompanying notes to condensed financial statements.

**Table of Contents**

**NEUROLOGIX, INC. AND SUBSIDIARY**  
**(A Development Stage Company)**  
**Notes to Unaudited Condensed Financial Statements**  
**(In thousands, except for share and per share amounts)**

**(1) Description of Business**

Neurologix, Inc. ( Neurologix or the Company ), is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system, primarily utilizing gene therapies. These treatments are designed as alternatives to conventional surgical and pharmacological treatments. The Company has not generated any operating revenues and, accordingly, it is a development stage company.

The Company incurred net losses of \$7,137, \$3,279 and \$41,439 and negative cash flows from operating activities of \$4,013, \$3,400 and \$31,621 for the six months ended June 30, 2009 and 2008 and for the period from February 12, 1999 (inception) to June 30, 2009, respectively. The Company expects that it will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future.

The Company had cash and cash equivalents of \$14,736 and \$18,906 as of June 30, 2009 and December 31, 2008, respectively. Management believes that the Company's current resources will enable it to continue as a going concern through at least June 30, 2010. The Company's existing resources, however, are not sufficient to allow it perform all of the clinical trials required for drug approval and marketing. Accordingly, it will, from time to time, continue to seek additional funds through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements. The Company does not know whether additional financing will be available when needed, or, if available, will be on acceptable or favorable terms to it or its stockholders. If the Company is unable to secure additional funding in the second half of 2009 or shortly thereafter, its ability to continue as a going concern may be in doubt.

**(2) Basis of Presentation**

The accompanying unaudited financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (the 2008 10-K ) filed with the Securities and Exchange Commission (the SEC ) on March 25, 2009. The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States ( GAAP ) for interim financial information, the instructions to Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The December 31, 2008 consolidated balance sheet information was derived from the audited consolidated financial statements as of that date.

**Table of Contents****(3) Summary of Significant Accounting Policies****(a) Stock-Based Compensation:**

At June 30, 2009, the Company had one active share-based employee compensation plan available for grants to employees, non-employee directors and consultants. Stock option awards granted from this plan are granted at the fair market value on the date of grant, vest over a period determined at the time the options are granted, ranging from zero to three years, and generally have a maximum term of ten years. Certain options provide for accelerated vesting if there is a change in control (as defined in the plans) or if there is a termination of employment event for specified reasons set forth in certain employment agreements. When options are exercised, new shares of the Company's common stock, par value \$0.001 per share (the Common Stock), are issued.

The Company's accompanying unaudited statements of operations reflect share-based compensation expense, recorded in accordance with the provisions of Statement of Financial Accounting Standards (SFAS) No. 123R, Share-based Payment (SFAS 123R), for employee stock options and other share-based compensation using the modified prospective method.

The total value of the stock option awards is expensed ratably over the service period of the employees receiving the awards. As of June 30, 2009, total unrecognized compensation cost related to stock option awards, to be recognized as expense subsequent to June 30, 2009, was approximately \$345, and the related weighted-average period over which it is expected to be recognized was approximately 1 year.

The amount of compensation expense recognized under SFAS 123R during the three and six months ended June 30, 2009 and 2008 was comprised of the following:

	<b>Six Months Ended June</b>		<b>Three Months Ended June</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Research and development	\$ 90	\$ 90	\$ 72	\$ 53
General and administrative	215	235	160	153
Share-based compensation expense	\$ 305	\$ 325	\$ 232	\$ 206
Net share-based compensation expenses per basic and diluted common share	\$ (0.01)	\$ (0.01)	\$ (0.01)	\$ (0.01)

**Table of Contents**

A summary of option activity as of June 30, 2009 and changes during the six months then ended is presented below:

<b>Options</b>	<b>Shares Subject to Option (000)</b>	<b>Weighted- Average Exercise Price</b>	<b>Weighted- Average Remaining Contractual Term (years)</b>	<b>Aggregate Intrinsic Value</b>
Outstanding at December 31, 2008	3,623	\$ 1.38		
Granted	1,088	0.65		
Exercised				
Forfeited or expired	(37)	1.36		
Outstanding at June 30, 2009	4,674	\$ 1.21	6.81	\$ 0
Exercisable at June 30, 2009	3,570	\$ 1.37	6.31	\$ 0

The weighted-average grant-date fair value of options granted during the six months ended June 30, 2009 and 2008 was \$0.52 and \$0.46, respectively and was estimated using the Black-Scholes option pricing model.

The fair value of each stock option award is estimated under SFAS 123R on the date of the grant using the Black-Scholes option pricing model based on the assumptions noted in the following table:

	Six Months Ended June 30,	
	2009	2008
Expected option term	5-6	5-6
Risk-free interest rate	2.06%	3.79%
Expected volatility	116%	91%
Dividend yield	0%	0%

Expected volatility is based on historical volatility of the Common Stock. The risk-free rate is based on the five-year U.S. Treasury security rate.

The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin No. 107 (SAB 107), which averages an award's weighted-average vesting period and expected term for plain vanilla share options. Under SAB 107, options are considered to be plain vanilla if they have the following basic characteristics: granted at-the-money; exercisability is conditioned upon service through the vesting date; termination of service prior to vesting results in forfeiture; limited exercise period following termination of service; and options are non-transferable and non-hedgeable.

In December 2007, the SEC issued Staff Accounting Bulletin No. 110 (SAB 110). SAB 110 was effective January 1, 2008 and expresses the views of the staff of the SEC with respect to extending the use of the simplified method, provided in SAB 107, in developing an estimate of the expected term of plain vanilla share options in accordance with SFAS 123R. The Company will continue to use the simplified method until it has the historical data necessary to provide a reasonable estimate of expected life in accordance with SAB 107, as amended by SAB 110. For the expected option term, the Company has plain-vanilla stock options and, therefore, used a simple average of the vesting period and the contractual term for options granted subsequent to January 1, 2006 as permitted by SAB 107.

**Table of Contents**

For equity awards to non-employees, the Company also applies the Black-Scholes option pricing model to determine the fair value of such instruments in accordance with SFAS 123R and Emerging Issues Task Force Issue 96-18,

Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods, or Services. The options granted to non-employees are re-measured as they vest and the resulting value is recognized as an adjustment against the Company's net loss over the period during which the services are received.

**(b) Basic and Diluted Net Loss Per Common Share:**

Basic net loss per common share excludes the effects of potentially dilutive securities and is computed by dividing net loss applicable to common stock by the weighted average number of common shares outstanding for the period.

Diluted net income or loss per common share is adjusted for the effects of convertible securities, options, warrants and other potentially dilutive financial instruments only in the periods in which such effects would have been dilutive.

The following securities were not included in the computation of diluted net loss per share because to do so would have had an anti-dilutive effect for the periods presented:

	<b>Six Months Ended June 30,</b>	
	<b>2009</b>	<b>2008</b>
Stock options	4,673,833	3,783,333
Warrants	7,441,920	7,441,920
Common Stock issuable upon conversion of Series A Convertible Preferred Stock	645	645
Common Stock issuable upon conversion of Series C Convertible Preferred Stock	7,115,238	6,739,709
Common Stock issuable upon conversion of Series D Convertible Preferred Stock	24,634,497	22,996,618

**(c) Derivative Instruments:**

The Company accounts for derivatives in accordance with SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities (SFAS 133), which provides accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts. All derivatives are recorded on the Company's balance sheet at fair value in accordance with current accounting guidelines for such complex financial instruments. (See Note 4 and Note 5).



**Table of Contents**

Effective January 1, 2009, the Company adopted SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities an amendment of FASB Statement No. 133 ( SFAS 161 ). SFAS 161 requires entities that utilize derivative instruments to provide qualitative disclosures about their objectives and strategies for using such instruments, as well as any details of credit-risk-related contingent features contained within derivatives. SFAS 161 also requires entities to disclose additional information about the amounts and location of derivatives located within the financial statements, how the provisions of SFAS 133 have been applied and the impact that hedges have on an entity's financial position, financial performance and cash flows. The Company's derivative liabilities are related to warrants issued in connection with financing transactions and are therefore not designated as hedging instruments.

***(d) Financial Instruments and Fair Value:***

Effective January 1, 2008, the Company adopted SFAS No. 157, Fair Value Measurements ( SFAS 157 ), for financial assets and liabilities. SFAS 157 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under SFAS 157 are described below:

*Level 1* Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

*Level 2* Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and

*Level 3* Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

In estimating the fair value of the Company's derivative liabilities, the Company used the probability-weighted Black-Scholes option pricing model. (See Note 4 and Note 5).

***(e) Recent Accounting Pronouncements:***

In April 2009, the Financial Accounting Standards Board ( FASB ) issued FASB Staff Position 107-1, Interim Disclosures about Fair Value of Financial Instruments ( FSP 107-1 ). FSP 107-1 amends FASB Statement No. 107, Disclosures about Fair Value of Financial Instruments, to require disclosures about fair value of financial instruments of publicly traded companies for interim reporting periods of publicly traded companies as well as in annual financial statements. FSP 107-1 also amends Accounting Principles Board Opinion No. 28, Interim Financial Reporting ( APB 28-1 ), to require those same disclosures in summarized financial information at interim reporting periods beginning after March 15, 2009. The Company adopted the provisions of FSP 107-1 on June 30, 2009.

**Table of Contents**

In May 2009, the FASB issued FASB Statement No. 165, Subsequent Events ( FAS 165 ) effective for interim financial periods ending after June 15, 2009. FAS 165 establishes principles and requirements for subsequent events. FAS 165 defines the period after the balance sheet date during which events or transactions that may occur would be required to be disclosed in a company's financial statements. Public entities are required to evaluate subsequent events through the date that financial statements are issued. FAS 165 also provides guidelines in evaluating whether or not events or transactions occurring after the balance sheet date should be recognized in the financial statements. FAS 165 requires disclosure of the date through which subsequent events have been evaluated. The Company has evaluated subsequent events through the date of issuance of this report.

**(4) Derivative Financial Instruments**

Effective January 1, 2009, the Company adopted EITF Issue No. 07-05, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock ( EITF 07-05 ). EITF 07-05 clarifies the determination of whether an instrument issued by an entity (or an embedded feature in the instrument) is indexed to an entity's own stock, which would qualify as a scope exception under SFAS 133.

Based upon the Company's analysis of the EITF 07-05 criteria, certain warrants (the Warrants ) issued in connection with the issuance of the Series C Convertible Preferred Stock, par value \$0.10 per share, and the Series D Convertible Preferred Stock, par value \$0.10 per share, must now be treated as derivative liabilities in the Company's balance sheet. Prior to the adoption of EITF 07-05, the Company accounted for the Warrants as components of stockholders equity under SFAS 133.

Consistent with EITF 07-05's requirements, the Company recognized the cumulative effect of the change in accounting principle to reduce the opening balance of the deficit accumulated during the development stage for fiscal year 2009. The cumulative effect adjustment of \$5,182 represents the difference between the amounts recognized in the balance sheet before initial application of EITF 07-05 on January 1, 2009. Additionally, the initial fair value of the Warrants, aggregating \$6,252, which were initially recorded as additional paid-in capital upon issuance, was reclassified to long-term liabilities upon adoption of EITF 07-05. The amounts recognized at initial issuance were determined based on the estimated fair value of the Warrants using a probability-weighted Black-Scholes option pricing model. Prospectively, the Warrants will be re-measured at each balance sheet date based on estimated fair value, and any resultant changes in fair value will be recorded as non-cash valuation adjustments within other income (expense) in the Company's statement of operations. During the six months ended June 30, 2009, the Company recorded other expense of \$1,980 relating to the change in fair value of the Warrants during this period. During the three months ended June 30, 2009, the Company recorded other income of \$809 relating to the change in fair value of the Warrants during this period.

The Company estimates the fair value of the Warrants using the probability-weighted Black-Scholes option pricing model. The assumptions used for the six months ended June 30, 2009 are noted in the following table:

	Three and Six Months Ended June 30, 2009	
Expected option term	5 to 7 years	
Risk-free interest rate	2.54%	3.19%
Expected volatility	122%	
Dividend yield	0%	

**Table of Contents**

Expected volatility is based on historical volatility of the Company's common stock. The Warrants have a transferability provision and based on guidance provided in SAB 107 for options issued with such a provision, the Company used the full contractual term as the expected term of the Warrants. The risk free rate is based on the five-year and seven-year U.S. Treasury security rates.

**(5) Fair Value Measurements**

The following table presents the Company's liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of June 30, 2009:

<b>Description</b>	<b>Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)</b>	<b>Significant Other Observable Inputs (Level 2)</b>	<b>Significant Unobservable Inputs (Level 3)</b>	<b>Balance as of June 30, 2009</b>
Derivative liabilities related to Warrants	\$	\$	\$ 3,050	\$ 3,050

The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the six months ended June 30, 2009:

<b>Description</b>	<b>Balance at December 31, 2008</b>	<b>Cumulative Effect of the Adoption of EITF 07-05 (See Note 4)</b>	<b>Unrealized Losses</b>	<b>Balance as of June 30, 2009</b>
Derivative liabilities related to Warrants	\$	\$ 1,070	\$ 1,980	\$ 3,050

The unrealized losses on the derivative liabilities are classified in other expenses as a change in derivative liabilities in the Company's statement of operations. Fair value is determined based on a probability-weighted Black-Scholes option pricing model calculation. (See Note 4).

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company performs a detailed analysis of the assets and liabilities that are subject to SFAS 157. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

**Table of Contents**

**(6) Commitments and Contingencies**

***Consulting Agreements:***

In May 2009, the Company entered into consulting agreements with former directors Austin M. Long, III and Craig J. Nickels to utilize their knowledge and skills to provide valuable services to the Company with respect to its financing and business development activities in 2009. Under the consulting agreements, each of them will receive \$1,000 per month through December 31, 2009. The total amount charged to operations in connection with the consulting agreements was \$3 for the three and six months ended June 30, 2009.

In addition, Messrs. Long and Nickels were each granted stock options to purchase 100,000 shares of Common Stock at an exercise price of \$0.65 per share. One half of the stock options vested on the date of grant, and the other half will vest on December 31, 2009.

**(7) Subsequent Event**

On July 23, 2009, the Company entered into Amendment No. 3 (the Amendment ) to its Clinical Study Agreement (the Agreement ), dated as of July 2, 2003, as amended, with Cornell University for and on behalf of its Joan & Sanford I. Weill Medical College ( Cornell ). The Amendment extends the performance period of the Sponsored Research Program referenced in Section 3 of the Agreement and eliminates certain activities from the Scope of Work referenced in Section 1 of the Agreement.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion should be read in conjunction with the unaudited financial statements and accompanying notes in this quarterly report on Form 10-Q and the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (the 2008 10-K ). Operating results are not necessarily indicative of results that may occur in future periods. All amounts in this Item 2 are in thousands.

**Business Overview**

The Company is a development stage company that is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system using gene transfer and other innovative therapies. These treatments are designed as alternatives to conventional surgical and pharmacological treatments.

To date, the Company has not generated any operating revenues and has incurred annual net losses. From inception through June 30, 2009, the Company had an accumulated deficit of \$45,205, and it expects to incur additional losses in the foreseeable future. The Company recognized net losses of \$7,137 for the six months ended June 30, 2009, and \$3,279 for the six months ended June 30, 2008.

**Table of Contents**

Since its inception, the Company has financed its operations primarily through sales of its equity and debt securities. From inception through June 30, 2009, the Company received proceeds primarily from private sales of equity and debt securities and from its merger in February 2004 of approximately \$44,531 in the aggregate.

The Company has devoted a significant portion of its capital resources to the research and development of its products. The Company's primary efforts are directed to the development of a therapeutic product to meet the needs of patients suffering from Parkinson's disease.

In addition to its product for Parkinson's disease, the Company is undertaking efforts to develop a product for the treatment of Huntington's disease and has undertaken efforts to develop a product for temporal lobe epilepsy (TLE). Based on a recent review of the results of its latest pre-clinical study relating to Huntington's disease, the Company is currently further analyzing those results in order to decide what, if any, additional pre-clinical studies need to be conducted so as to be in a position to obtain approval for a Phase 1 clinical trial. The timing of such trial is subject to the completion of the above-mentioned analysis, the successful completion of additional pre-clinical studies, if any, the availability of funding, the availability of the adeno-associated virus (AAV) vector and an infusion system and to the receipt of applicable regulatory approvals. The Company believes that its current resources are sufficient to conduct the above-mentioned analysis and any potential additional pre-clinical studies. The Company does not anticipate using its current funds for the further development of its TLE product at this time. See Plan of Operation Huntington's disease and Plan of Operation Epilepsy below.

**Plan of Operation**

*Parkinson's Disease*

In October 2006, the Company announced that it had completed its Phase 1 clinical trial for Parkinson's disease. The results of this trial indicate that the treatment appears to be safe and well-tolerated in trial participants with advanced Parkinson's disease, with no evidence of adverse effects or immunologic reaction related to the study treatment. The trial, in which treatment was confined to only one side of the brain, also yielded statistically significant clinical efficacy and neuroimaging results. The results were peer-reviewed and published in the June 23, 2007 issue of the journal *The Lancet* and the online edition of the *Proceedings of the National Academy of Sciences* in November 2007. In December 2008, the Company initiated a Phase 2 clinical trial for Parkinson's disease. This trial is a randomized, controlled study designed to further establish the effectiveness and the safety of the treatment. The trial is being conducted in multiple medical centers throughout the U.S. with an expected 40 trial participants, 20 of which will be randomly selected to receive the treatment and 20 of which will be randomly selected to receive a sterile saline solution.

In June 2009, the Data Monitoring Committee (the DMC), a group of independent medical experts, selected by the Company, who are responsible for reviewing and evaluating the safety data generated from the Company's Phase 2 clinical trial, recommended the continuation of the clinical trial. This recommendation was based on the DMC's review of all data from the first 7 patients enrolled in the clinical trial with at least one month of data.

**Table of Contents**

The Company expects to conclude the surgeries for its Phase 2 clinical trial in the second half of 2009 and announce initial efficacy data in the first half of 2010. The Company will take steps to move toward a pivotal trial for treatment of Parkinson's disease, and hopes to be in a position to file its protocol with the U.S. Food and Drug Administration (FDA) in 2011. The Company's conduct of such trial will require, among other things, approval by the FDA. Currently, the Company estimates that the pivotal trial could be completed in 2013 and the estimated total costs to reach that milestone are expected to be in excess of \$20,000.

*Huntington's disease*

In November 2005, the Company announced findings from pre-clinical studies which showed that a form of the gene XIAP (X-linked Inhibitor of Apoptosis Protein or dXIAP) may prevent the progression of Huntington's disease. The Company further investigated the neuroprotective effects of dXIAP by injecting presymptomatic rodents with AAV vectors encoding dXIAP into the striatum, an area of the brain normally affected in Huntington's patients. In the study, rodents injected with this vector experienced significant reversal of motor dysfunction to the level of normal rodents, while there was no improvement in rodents treated with a control vector. dXIAP also improved the function of the diseased neurons in culture. Furthermore, no adverse effects due to dXIAP overproduction were observed.

In August 2008, the Company entered into a license agreement with respect to an exclusive license for the worldwide rights, excluding China, for the use of dXIAP for therapeutic or prophylactic purposes in the treatment of Huntington's disease.

The Company's development of this therapy for Huntington's disease is currently in the pre-clinical phase. The Company is presently conducting a further review and analysis of its pre-clinical results in order to determine how to best proceed to obtain regulatory clearance to commence a Phase 1 clinical trial for this therapy. The timing of such trial is subject to the completion of such review and analysis as well as the other factors specified above in Business Overview.

*Epilepsy*

In December 2006, the Company submitted an investigational new drug application to the FDA for permission to begin a Phase 1 clinical trial in TLE. The proposed clinical protocol for this study was presented to the National Institute of Health's Office of Biotechnology Activities Recombinant DNA Advisory Committee on September 23, 2004 and reviewed favorably.

During the second quarter of 2008, the Company learned that further action is required to protect adequately the Company's intellectual property rights in its technology relating to its TLE product. The Company recently discovered that certain individuals, not affiliated with the Company, may also have rights to use certain technology currently used by the Company with respect to the TLE product. If the Company elects to proceed with its Phase 1 clinical trial for its TLE product, the Company will need to conduct an additional pre-clinical study in non-human primates, which would be conducted in accordance with guidance received from the FDA.

**Table of Contents**

Based on the foregoing, the commencement of a Phase 1 clinical trial for the Company's TLE product will be subject, among other things, to the successful resolution of the above mentioned intellectual property issues, to the successful completion of an additional pre-clinical study, the availability of funding, concurrence by the FDA and procurement of related intellectual property licenses. The Company does not anticipate using its current funds for the further development of its TLE product at this time.

*Other Therapies*

The Company will also continue its efforts in developing therapies to treat other neurodegenerative and metabolic disorders, including depression and genetically-based obesity under its research agreements with Cornell University for and on behalf of its Joan & Sanford I. Weill Medical College and Ohio State University.

*Future Operating Expenditures*

Over the next 12 months, in addition to its normal recurring expenditures, the Company expects to spend approximately \$5,000 in Phase 2 clinical trial expenses with regard to its Parkinson's treatment; \$1,000 in costs associated with operating as a publicly traded company, such as legal fees, accounting fees, insurance fees, insurance premiums, investor and public relations fees; \$700 in research and licensing fees; and \$500 in costs associated with scaling up its manufacturing capabilities for the supply of product for a Parkinson's pivotal trial.

**Results of Operations**

**Three Months Ended June 30, 2009 Compared to the Three Months Ended June 30, 2008**

*Revenues.* The Company did not generate any operating revenues in the three months ended June 30, 2009 or in the three months ended June 30, 2008.

*Costs and Expenses.*

*Research and Development.* Research and development expenses increased by \$1,502 during the three months ended June 30, 2009 to \$2,249 as compared to \$747 during the comparable period in 2008. The increase was mainly due to a \$1,157 increase in expenses related to the Company's Phase 2 clinical trial for Parkinson's disease, as well as a \$151 increase in process development expenses for large scale manufacturing of the Company's products and infusion devices, a \$124 increase in pre-clinical costs associated with its Huntington's disease product and a \$74 increase in cash and non-cash employee compensation expense.

*General and Administrative.* General and administrative expenses decreased by \$40 to \$799 during the three months ended June 30, 2009, as compared to \$839 during the comparable period in 2008. This decrease was due mainly to a \$40 decrease in professional fees, including an \$85 decrease in legal fees and a \$21 decrease in investor and public relations fees, offset by a \$56 increase in cash and non-cash compensation to Company consultants and a \$10 increase in accounting fees.

**Table of Contents**

*Other Income (Expense), Net.* The Company had net other income of \$825 during the three months ended June 30, 2009, as compared to net other income of \$155 during the comparable period in 2008. The change is mainly due to income of \$809 recognized for the decrease in estimated fair value of its derivative liabilities during the three months ended June 30, 2009. Additionally, the Company earned \$139 less in interest income during the three months ended June 30, 2009 as compared to the comparable period in 2008.

**Six Months Ended June 30, 2009 Compared to the Six Months Ended June 30, 2008**

*Revenues.* The Company did not generate any operating revenues in the six months ended June 30, 2009 or in the six months ended June 30, 2008.

*Costs and Expenses.*

*Research and Development.* Research and development expenses increased by \$1,829 during the six months ended June 30, 2009 to \$3,658 as compared to \$1,829 during the comparable period in 2008. The increase was mainly due to a \$1,111 increase in expenses related to the Company's Phase 2 clinical trial for Parkinson's disease, as well as a \$253 increase in process development expenses for large scale manufacturing of the Company's products and infusion devices, a \$252 increase in fees related to license agreements and sponsored research agreements and a \$156 increase in pre-clinical costs associated with its Huntington's disease product.

*General and Administrative.* General and administrative expenses decreased by \$213 to \$1,548 during the six months ended June 30, 2009, as compared to \$1,761 during the comparable period in 2008. This decrease was due, in part, to a \$102 decrease in professional fees, including legal fees, accounting fees, investor and public relations fees, as well as a \$72 decrease in employee compensation expense, and a \$29 reduction in patent impairment charges.

*Other Income (Expense), Net.* The Company had net other expenses of \$1,931 during the six months ended June 30, 2009, as compared to net other income of \$311 during the comparable period in 2008. The change is mainly due to other expense of \$1,980 recognized for the decrease in estimated fair value of its derivative liabilities during the six months ended June 30, 2009. Additionally, the Company earned \$262 less in interest income during the six months ended June 30, 2009 as compared to the comparable period in 2008.

**Liquidity and Capital Resources**

Cash and cash equivalents were \$14,736 at June 30, 2009.

The Company is a development stage company and has not generated any operating revenues as of June 30, 2009. In addition, the Company will continue to incur net losses and cash flow deficiencies from operating activities in the foreseeable future.

Based on its cash flow projections, the Company believes that its current resources will enable it to continue as a going concern through at least June 30, 2010. The Company's existing resources, however, are not sufficient to allow it to perform all of the clinical trials required for drug approval and marketing, including a pivotal trial for Parkinson's disease. Accordingly, it will, from time to time, continue to seek additional funds through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements. The Company does not know whether additional financing will be available when needed or, if available, will be on acceptable or favorable terms to it or its stockholders. If the Company is unable to secure additional funding in the second half of 2009 or shortly thereafter, its ability to continue as a going concern may be in doubt.



**Table of Contents**

Net cash used in operating activities was \$4,013 for the six months ended June 30, 2009 as compared to \$3,400 during the comparable period in 2008. The \$613 increase in net cash used in operations was primarily due to a \$3,858 increase in net loss, offset by \$2,049 in adjustments to net loss for increased non-cash expenses, as well as a \$1,203 increase in working capital in 2009.

The Company had net cash used in investing activities of \$157 during the six months ended June 30, 2009 as compared to \$145 during the six months ended June 30, 2008. Cash used in investing activities relates to purchases of equipment and additions to intangible assets made by the Company during 2009 and 2008.

The Company had no net cash used in or provided by financing activities during the six months ended June 30, 2009.

Net cash provided by financing activities during the six months ended June 30, 2008 was \$4,957, which represented net proceeds received by the Company in a private placement of its Series D Stock in April 2008.

**FORWARD-LOOKING STATEMENTS**

This document includes certain statements of the Company that may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words expects, anticipates, estimates, plans, intends, projects, predicts, believes, may, should, and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events and are subject to numerous risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among other things:

- the inability of the Company to raise additional funds, when needed, through public or private equity offerings, debt financings or additional corporate collaboration and licensing arrangements; and
- the inability of the Company to successfully commence and complete all necessary clinical trials for the commercialization of its product to treat Parkinson's disease.

**Table of Contents**

Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information regarding factors which could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" contained in the 2008 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Not applicable.

**Item 4. Controls and Procedures**

(a) *Disclosure Controls and Procedures.* The Company maintains disclosure controls and procedures as required under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Exchange Act, that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As of June 30, 2009, the Company's management carried out an evaluation, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of its disclosure controls and procedures. Based on the foregoing, its Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of June 30, 2009.

(b) *Changes in Internal Control Over Financial Reporting.* There were no changes in the Company's internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Table of Contents**

## PART II. OTHER INFORMATION

**Item 4. Submission of Matters to a Vote of Security Holders**

The Company's Annual Meeting of Stockholders was held on May 7, 2009 (the Annual Meeting ). There were present at the Annual Meeting in person or by proxy stockholders holding an aggregate of 20,913,564 shares of Common Stock, 274,831 shares of Series C Stock and 734,898 shares of Series D Stock. All shares of Preferred Stock account for an additional 28,185,565 shares of Common Stock on an as converted basis, based upon the Series C Stock adjusted conversion price of \$1.60 per share and the Series D Stock initial conversion price of \$1.16 per share. At the Annual Meeting, John E. Mordock, the nominee for Class III director, was elected. The number of votes on an as converted to common basis for the nominee is set forth below:

Name of Director Nominee	Number of Votes For	Number of Votes Withheld	Number of Votes Abstaining	Number of Broker Non-Votes
John E. Mordock	48,833,986	265,143	0	0

William J. Gedale, Clark A. Johnson and Jeffrey B. Reich, M.D., the Class I directors and Cornelius E. Golding, Martin J. Kaplitt, M.D. and Elliott H. Singer, the Class II directors, have terms which expire in 2010 and 2011, respectively. Accordingly, these directors were not up for re-election at the Annual Meeting and their terms of office continued after the Annual Meeting. Austin M. Long, III and Craig J. Nickels, two former Class III directors of the Company, did not stand for re-election at the Annual Meeting and their terms ended on May 7, 2009.

**Item 6. Exhibits**

See Exhibit Index.

**Table of Contents**

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**NEUROLOGIX, INC.**

August 12, 2009

/s/ John E. Mordock  
John E. Mordock  
President and Chief Executive Officer  
(as Principal Executive Officer)

August 12, 2009

/s/ Marc L. Panoff  
Marc L. Panoff  
Chief Financial Officer, Secretary and Treasurer  
(as Principal Accounting Officer/Principal  
Financial Officer)

**Table of Contents**

**EXHIBIT INDEX**

Exhibit No.	Exhibit
31.1	Rule 13a-14(a)/15d-14(a) Certification of President and Chief Executive Officer (as Principal Executive Officer).**
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer, Secretary and Treasurer (as Principal Accounting Officer/Principal Financial Officer).**
32.1	Section 1350 Certification of Chief Executive Officer and Chief Financial Officer, Secretary and Treasurer.**

\*\* Filed herewith.